

CLAIMS

1. A combination of (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor.

5 2. A combination of (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor, for use as a medicament.

10 3. A combination of (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor, for administration simultaneously, separately or sequentially, for use as a medicament for the treatment of a disease or disorder that may be treated by antagonism of either or both of the histamine H<sub>1</sub> and H<sub>4</sub> receptors such as allergic rhinitis or asthma.

15 4. The use of a combination of (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor, for administration simultaneously, separately or sequentially, for the manufacture of a medicament for the treatment of a disease or disorder that may be treated by antagonism of either or both of the histamine H<sub>1</sub> and H<sub>4</sub> receptors such as allergic rhinitis or asthma.

20 5. A method of treatment of a mammal, including a human being, to treat a disease or disorder that may be treated by antagonism of either or both of the histamine H<sub>1</sub> and H<sub>4</sub> receptors such as allergic rhinitis or asthma including simultaneous, separate or sequential administration to the mammal of a (a) an effective amount of a histamine H<sub>1</sub> receptor antagonist and (b) an effective amount of an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor.

25 6. A pharmaceutical composition including (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor, and a pharmaceutically acceptable excipient, diluent or carrier.

30 7. A product containing (a) a histamine H<sub>1</sub> receptor antagonist and (b) an antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor as a combined preparation for simultaneous, separate or sequential use in the treatment of a disease or disorder that may be treated by antagonism of either or both of the histamine H<sub>1</sub> and H<sub>4</sub> receptors such as allergic rhinitis or asthma.

35 8. An antagonist that is at least 10-fold selective for the histamine H<sub>4</sub> receptor as compared to the histamine H<sub>3</sub> receptor.

9. A pharmaceutical composition including an antagonist as claimed in claim 8 and a pharmaceutically acceptable excipient, diluent or carrier.

10. An antagonist as claimed in claim 8 or composition as claimed in claim 9 for use as a medicament.
11. An antagonist as claimed in claim 8 or composition as claimed in claim 9 for use as a medicament for the treatment of a disease or disorder that may be treated by antagonism of the histamine H<sub>4</sub> receptor such as allergic rhinitis or asthma.
- 5 12. The use of an antagonist as claimed in claim 8 or a composition as claimed in claim 9 for the manufacture of a medicament for the treatment of a disease or disorder that may be treated by antagonism of the histamine H<sub>4</sub> receptor such as allergic rhinitis or asthma.
13. A method of treatment of a mammal, including a human being, to treat a 10 disease or disorder that may be treated by antagonism of the histamine H<sub>4</sub> receptor such as allergic rhinitis or asthma which includes administration to the mammal of an effective amount of an antagonist as claimed in claim 8 or a composition as claimed in claim 9.